Gerrard Terlouw

Today marks the last day of #ESMO24! Check out our take on the highlights and trends below. If you're onsite, stop by booth 431e to meet the Inizio team and learn more. #Oncology #ReimagineHealth #Biopharma #Healthcare

7

A nice short HBR read as we are trying to modernize our ways of working, drive thoughtful risk taking and empower our talents for more innovation, more value creation — Many thanks Jasmine Chang for sharing !

53

2 Kommentare

AbbVie today announced that the European Commission has approved SKYRIZI® (risankizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. "Ulcerative colitis is a chronic, unpredictable and sometimes debilitating disease, and people living with the condition need sustained symptom relief," said Edouard Louis, M.D., Ph.D., professor and head of gastroenterology, Liège University Hospital, dean of faculty, University of Liège, and INSPIRE trial investigator. "Patients treated with SKYRIZI in the INSPIRE and COMMAND clinical trials experienced significant improvements in clinical remission and mucosal healing. These are important findings as mucosal healing goes beyond symptom management to restoration of the intestinal lining and is associated with improved long-term outcomes. This approval introduces a new treatment option to help patients with UC reach their long-term treatment goals," continued Professor Louis. UC is estimated to affect 5 million people around the world, and the incidence is increasing worldwide. The common signs and symptoms of UC include diarrhea, abdominal pain, blood in the stool, urgency to defecate, passing mucus from the rectum and rectal pain and bleeding. Because of the pain and discomfort, patients commonly lack the ability or desire to pursue everyday activities. "The approval of SKYRIZI for the treatment of UC provides physicians with a new treatment option that is proven to help a wide range of patients with varying degrees of prior therapy use, including conventional or biological therapy. Notably, in the Phase 3 trials we observed positive results in mucosal healing particularly in patients without previous biologic experience or JAK inhibitor failure," said Roopal Thakkar, M.D., executive vice president, research & development, and chief scientific officer, AbbVie. "The EU approval of SKYRIZI for people living with UC strengthens our diversified IBD portfolio, providing healthcare professionals with more options to treat their IBD patients."  #immunology #gastroenterology #ulcerativecolitis #IBD #UC #risankizumab #SKYRIZI #AbbVie

50

The newly issued guidelines from SFDA propose a gradual implementation of general requirements and economic studies as part of a new dossier submission. Our pharma experts dive into the impact on the P&MA landscape, the challenges, opportunities, and strategies for a successful market entry. skp.link/d5sl #BetterMarketAccess #SFDA #Vision2030 #SaudiArabia #Pharma #SimonKucher

10

As I am sure everyone has felt this year, the pharma market has been in a difficult place. Facing a perfect storm of high interest rates, margin pressures from the US' IRA and other spending containment measures, and an impending LoE cliff, manufacturers have been forced to reassess many aspects of their business. This has resulted in large-scale, industry-wide pipeline assessment and realignment, with Roche's journey being a prime example of such portfolio management, cutting 25% of its pipeline and focusing on areas like obesity and ophthalmology.   What does this mean for service companies like Envision? Clearly, with fewer products in the pipeline, we could see this as a threat, but I think it represents an opportunity to reinforce the value of the expertise we bring to the industry. With companies having fewer products in the pipeline, there are higher stakes to ensure therapies are developed and commercialized effectively. We can bring confidence through our experience of being involved in multiple launches and certainty through our ability to use our proprietary AI to help mitigate risk and increase the speed of decision-making. In a world where resources are finite, manufacturers should see agencies such as Envision as critical partners to bring the most promising treatments to market. Hence, they can continue to advance the standard of care and improve patient outcomes. https://lnkd.in/eEbCet_y

27

2 Kommentare

2023 was a big year for Grünenthal! Our latest annual report is now available, providing insight into our exciting journey and transformative vision. 🚀 At Grünenthal, we touch the lives of millions of patients worldwide with innovative treatments that can give them the quality of life they deserve. We are striving to achieve our vision of a #WorldFreeofPain by pursuing two key strategic approaches. First, we are targeting organic growth by focusing our R&D activities on pain management. Second, we are tapping into inorganic growth by acquiring assets that strengthen our established medicine portfolio – no matter which therapeutic area. These deals significantly boost our profitability, which enables us to continue investing in pain innovation. Our latest joint venture collaboration with Kyowa Kyrin International gives Grünenthal access to 13 life-changing brands across six therapeutic areas. That makes it an excellent fit for our business and empowers us to reach even more patients around the globe. Learn more about our joint venture Grünenthal Meds and why we might be the right partner for you too, in our latest Grünenthal Report: https://lnkd.in/eMUhjaiy #WorldFreeofPain #WeAreGrünenthal

69

1 Kommentar

Last week’s half year results announcement at Boehringer Ingelheim shed light on our strong pipeline plans and our unwavering focus on addressing unmet patient need. While we have discussed our pipeline before, in the past few months especially we have had well-rounded progress on several of our focus therapy areas, showcasing once again our commitment to innovation addressing patient need.   1. Cardiovascular, renal and metabolic (CRM) health – Our recent groundbreaking phase II trial success in adults with MASH (metabolic dysfunction-associated steatohepatitis) and liver fibrosis gives new hope to people living with connected CRM diseases. Our multi-year sponsorship of the American Heart Association's Cardiovascular-Kidney-Metabolic Health Initiative will allow us to better understand the burden of people affected by diseases in these interconnected conditions and enable better care. 2. Oncology: Phase Ia/Ib trial of a HER2-specific tyrosine kinase inhibitor in patients with HER2 aberration-positive solid tumors demonstrated promising efficacy. We are focusing our efforts in oncology with targeted investments aimed at making meaningful progress in promising trials with the ultimate goal of curing a range of cancers. 3. Mental health: “Rethinking mental health care: harnessing new approaches”, a study commissioned by Boehringer Ingelheim, uncovers the significant barriers and potential solutions to meet the growing, yet alarmingly unmet, demand for mental health services worldwide. 4. We signed nine R&D partnership agreements, significantly bolstering our human pharma portfolio across all therapeutic areas and tech platforms.   In the first half of the year alone, we initiated 28 clinical studies. We advanced our pipeline with five new phase I, II, or III initiations in cardiometabolic diseases, mental health and oncology, and achieved two additional fast track designations for programs in inflammation. All these achievements reflect our commitment to innovative patient care. By stepping up our investments in research and development, we are accelerating the delivery of breakthrough therapies that address healthcare's greatest challenges.   A big thank you to colleagues in Boehringer Ingelheim and our partners, who remain committed to a shared passion – value to patients!   The coming months and years present an excellent opportunity for us to transform lives for generations. It takes all of us in healthcare to make an impact, for patients to live better. Let us come together to enable an environment of innovation that reaches patients across the world, better and faster.   #LifeForward #boehringeringelheim #LiverDisease #Oncology #MentalHealth

624

13 Kommentare